Program
NVX-CoV2373 adjuvated lipid nanoparticle
Also written as “NVX-CoV2373”, “SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)” and “NVX-Cov2373”.
Its studies are mostly in COVID-19 · Severe Acute Respiratory Syndrome, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novavax | 120 open or running | phase 4since Oct 4, 2024 | Apr 24, 2020 | none ahead |
| Takeda | 20 open or running | phase 3since Mar 27, 2022 | Jan 14, 2021 | none ahead |
| Cogna Technology Solutions | 10 open or running | phase 3since Feb 18, 2022 | Feb 18, 2022 | none ahead |
| Sanofi | 11 open or running | phase 4since Sep 30, 2026 | Sep 30, 2026 | Nov 26, 2026phase 4 · NCT07861542 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 24, 2020First study: phase 2 study in COVID-19New to NovavaxNovavax · NCT04368988 · 1,419 enrolled · United States, Australia
- Aug 28, 2020Phase 2 study in COVID-19Novavax · NCT04533399 · 4,422 enrolled · South Africa
- Oct 9, 20202 phase 3 studiesNovavax · NCT04583995, NCT04611802
- Jan 14, 2021Takeda’s first study: phase 2 study in Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)New to TakedaTakeda · NCT04712110 · 200 enrolled · Japan
- Oct 25, 2021Phase 2 study in COVID-19Novavax · NCT05112848 · 384 enrolled · South Africa
- Feb 18, 2022Cogna Technology Solutions’ first study: phase 3 study in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)New to Cogna Technology SolutionsCogna Technology Solutions · NCT05249816 · 1,000 enrolled · United Arab Emirates
- Mar 27, 2022Phase 3 study in COVID-19Takeda · NCT05299359 · 150 enrolled · Japan
- May 9, 2022Phase 3 study in COVID-19Novavax · NCT05372588 · 1,340 enrolled · Australia
- Jul 14, 20222 phase 3 studies in COVID-19Novavax · NCT05463068, NCT05468736
- May 16, 2023Phase 3 study in COVID-19Novavax · NCT05875701 · 147 enrolled · United States
- Jun 27, 2023Phase 3 study in COVID-19Novavax · NCT05925127 · 994 enrolled · United States
- Mar 1, 2024Phase 3 study in COVID-19Novavax · NCT06291857 · 9,320 enrolled · Australia, New Zealand
- Oct 4, 2024Phase 4 study in COVID-19Novavax · NCT06633835 · 660 enrolled · United States
- Sep 30, 2026Sanofi’s first study: phase 4 study in COVID-19New to SanofiSanofi · NCT07861542 · 669 enrolled · United States
Ahead
- Nov 26, 2026Primary completion: phase 4 study in COVID-19Sanofi · NCT07861542
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07861542COVID-19 · United States | 4 | Active, not recruiting | Sanofi | Nov 26, 2026 | 669 |
| NCT06633835COVID-19 · United States | 4 | Completed | Novavax | Dec 30, 2024 | 660 |
| NCT06291857COVID-19 · Australia, New Zealand | 3 | Completed | Novavax | Dec 24, 2025 | 9,320 |
| NCT05925127COVID-19 · United States | 3 | Completed | Novavax | May 21, 2024 | 994 |
| NCT05875701COVID-19 · United States | 3 | Completed | Novavax | Nov 11, 2023 | 147 |
| NCT05468736COVID-19 · United States, Colombia, Dominican Republic and more | 3 | Completed | Novavax | Jan 16, 2024 | 3,600 |
| NCT05463068COVID-19 · United States | 3 | Completed | Novavax | Aug 17, 2022 | 911 |
| NCT05372588COVID-19 · Australia | 3 | Completed | Novavax | Jul 17, 2022 | 1,340 |
| NCT05299359COVID-19 · Japan | 3 | Completed | Takeda | Jun 11, 2022 | 150 |
| NCT05249816Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) · United Arab Emirates | 3 | Completed | Cogna Technology Solutions | May 4, 2023 | 1,000 |
| NCT05112848COVID-19 · South Africa | 2 | Completed | Novavax | May 23, 2022 | 384 |
| NCT04712110Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) · Japan | 2 | Completed | Takeda | Mar 28, 2022 | 200 |
| NCT04611802Severe Acute Respiratory Syndrome · United States, Mexico, Puerto Rico | 3 | Completed | Novavax | Apr 10, 2023 | 33,000 |
| NCT04583995COVID-19 · United Kingdom | 3 | Completed | Novavax | Mar 29, 2022 | 15,185 |
| NCT04533399COVID-19 · South Africa | 2 | Completed | Novavax | Dec 7, 2021 | 4,422 |
| NCT04368988COVID-19 · United States, Australia | 2 | Completed | Novavax | Jun 1, 2022 | 1,419 |
How it is read
Names in the registry
- “NVX-CoV2373”, 3 entries
- “SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)”, 2 entries
- “NVX-Cov2373”, 2 entries
- “TAK-019”, 2 entries
- “Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 13 studies
- Severe Acute Respiratory Syndrome, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.